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Little Impact of Antiplatelet Agents on Venous Thromboembolism 
after Hip Fracture Surgery
Since the late 1980s, low dose aspirin has been used to prevent stroke and ischemic heart 
disease. However, prophylactic effect of antiplatelets against venous thromboembolism 
(VTE), in patients who undergo hip fracture surgery (HFS) is controversial. Our purpose was 
to determine the incidence of symptomatic VTE after HFS and to evaluate whether 
antiplatelets reduce the development of symptomatic VTE following HFS. We 
retrospectively reviewed 858 HFS in 824 consecutive patients which were performed from 
May 2003 to April 2010 at an East Asian institute. We compared the incidence of 
symptomatic VTE in antiplatelet users and non-users using multivariate logistic regression 
analyses. Overall incidences of symptomatic pulmonary embolism including fatal 
pulmonary embolism, and symptomatic deep vein thrombosis in this study were 2.4% 
(21/858), and 3.5% (30/858), respectively. The incidence of symptomatic VTE was 4.8% 
(12/250) in antiplatelet users and 4.3% (26/608) in non-users (P = 0.718). It is suggested 
that antiplatelet agents are not effective in prevention of symptomatic VTE after HFS.
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INTRODUCTION
Venous thromboembolism (VTE), including deep vein throm-
bosis (DVT) and pulmonary embolism (PE), is a major cause of 
morbidity and mortality after hip fracture surgery (HFS). With-
out any thromboprophylaxis, the risk of developing DVT follow-
ing HFS is over 50% and that of developing PE is 7%-11% (1-3). 
Due to such a high incidence of VTE various thromboprophylac-
tic modalities have been recommended by several guidelines, in-
cluding the American Academy of Orthopaedic Surgeons (AAOS), 
the American College of Chest Physicians (ACCP), and Nation-
al Institute for Health and Clinical Excellence (NICE) (3-5).
  In contrast to the large number of studies on developing symp-
tomatic VTE following HFS from Western countries, very few 
studies have been reported from East Asia.
  Daily use of low dose aspirin to prevent thrombosis became 
popular even in healthy people without any history of cardiovas-
cular disease or cerebrovascular accident since the late 1980s (6, 
7). However, thromboprophylactic efficacy of antiplatelets in 
patients who undergo HFS is controversial (3-5).
  The purpose of this study was to determine the incidence of 
symptomatic VTE after HFS and to evaluate whether antiplate-
let users have a low incidence of symptomatic VTE (symptom-
atic DVT, PE and fatal PE) after HFS than non-users in Korean 
population. 
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 851 patients 
(887 hips), who underwent HFS for femoral neck and intertro-
chanteric fractures at single institute from May 2003 to April 2010. 
Twenty-eight patients (29 hips) who were treated with anticoag-
ulant, such as heparin and warfarin; 11 patients (11 hips) due to 
management for cerebro-vascular disease, 10 patients (11 hips) 
due to a history of thrombo-embolic event, 6 patients (6 hips) 
due to a cardiac disease and one patients (one hip) due to fem-
oro-popliteal bypass graft before surgery were excluded, leaving 
824 patients for the study.
  Of the 824 patients (858 hips), antiplatelet users were defined 
as those who had taken low-dose aspirin (81-100 mg) or other 
antiplatelet agents for the prevention of thrombotic cardiovas-
cular or cerebrovascular event before admission for HFS, stopped 
the antiplatelet medication 5 to 7 days prior to surgery, and re-
sumed medication 1 day to 3 days after the surgery. Two hun-
dred and forty five patients (250 hips) were identified as antiplate-
let users. The remaining 579 patients (608 hips) were classified Ji H-M, et al.  •  Symptomatic Venous Thromboembolism after Hip Fracture Surgery
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as non-users.
  In the antiplatelet users, there were 173 women and 72 men 
with a mean age of 77.6 yr at the time of operation. Their mean 
body mass index (BMI) was 22.1 kg/m
2. In the non-users, there 
were 414 women and 165 men with a mean age of 75.2 yr at the 
time of operation. Their mean BMI was 21.3 kg/m
2 (Table 1).
  No pharmacological or mechanical prophylaxis for VTE other 
than antiplatelet was done postoperatively in both groups. How-
ever, thigh-length antiembolic stockings were applied and the 
ankle pump was encouraged in bed during the hospitalization.
  One day to three days after the operation, closed suction drain-
age was removed and patients were mobilized with wheelchairs. 
Patients walked with restricted weight-bearing and use of assis-
tive devices (wheelchair, walker, crutches, or cane) 3 to 10 days 
after the operation. As their walking ability improved, their assis-
tive devices were changed appropriately by physical therapists.
  After the operation, we carefully monitored clinical signs of 
DVT including pain and tenderness in the calf or thigh, swell-
ing or erythema of the operated limb, and a positive Homans’ 
sign. When VTE was suspected, we consulted the patients to car-
diovascular physicians. A diagnosis of DVT was made using du-
plex ultrasonography or lower extremity CT angiography. A PE 
was confirmed by a ventilation/perfusion scan or pulmonary 
CT angiography. Patients who were diagnosed as having a DVT 
or PE were treated with warfarin.
  Most deaths due to PE related to the operation reportedly oc-
cur within 3 months and any death of unknown cause that oc-
curred within 3 months of operation is considered to be the re-
sult of PE (8-10). We confirmed the fatal PE, if present, from the 
death certificate.
  Patients were monitored for 1 week to 3 weeks in the ward. 
After discharge, patients were routinely followed at 6 weeks, 3 
months and 6 months after the operation with a specific inter-
est of VTE. Patients who had not returned on regularly sched-
uled visits were contacted by telephone.
  We compared the incidence of symptomatic VTE (DVT, PE 
and fatal PE) in both groups. We also assessed gender, age, BMI, 
ambulatory ability before injury according to Koval’s categories 
(11), type of fracture (femur neck fracture or intertrochanteric 
fracture), pathologic fracture, malignancy, type of surgery (ar-
throplasty or internal fixation), type of anesthesia (regional or 
general), co-morbidity assessed by American Society of Anes-
thesiologists (ASA) score, operation time, the length of time from 
fracture to surgery, and previous history of cerebrovascular or 
cardiovascular disease to determine the relationships between 
these variables and the development of VTE.
  Statistical analyses were planned to determine whether the 
perioperative use of antiplatelets reduced the incidence of symp-
tomatic VTE. All HFS were divided into 2 groups; the VTE group 
(symptomatic DVT, PE as well as fatal PE) and non-VTE group. 
To determine confounding factors, univariate comparisons be-
tween the VTE group and the non-VTE group were made based 
on the demographic data and operative parameters. Statistical 
significance of the differences between the 2 groups was deter-
mined by chi-square test for categorical variables and Student’s 
t-test for continuous variables. For the variables with a P value 
less than 0.1 in the univariate analyses, multivariate logistic re-
gression analyses using the enter method were performed. In 
the multivariate logistic regression, the dependent variable was 
whether the VTE occurred or not postoperatively. From the mul-
tivariate regression analyses, it was assessed whether use of an-
tiplatelet statistically reduced occurrence of VTE. Statistical anal-
yses were conducted with the SPSS for Windows statistical pack-
age (version 12.0; SPSS, Chicago, IL, USA), and P value less than 
0.05 was considered as significant.
Ethics statement
The design and protocol of this study were reviewed and ap-
proved by the institutional review board of the Seoul National 
University Bundang Hospital (IRB No. B-1006-103-118). The 
board waived informed consent. 
RESULTS
Among the 858 procedures, there were 4 deaths of unknown 
cause within 3 months after the HFS. Symptomatic DVT occurred 
in 30 patients. Of them, 13 patients suffered symptomatic PE. 
Four patients suffered symptomatic PE without DVT. Overall 
incidences of symptomatic PE including fatal PE, and symptom-
atic DVT in this study were 2.4% (21/858), and 3.5% (30/858), 
respectively. The incidence of symptomatic VTE was 4.8% (12/ 
250) in antiplatelet users and 4.3% (26/608) in non-users (P =  
0.718). In the univariate comparisons, only gender showed P 
value less than 0.1 (Table 2).
  Multivariate logistic regression analyses for the variables with 
a P value less than 0.1 in the univariate analyses demonstrated 
that no variable was significantly associated with the VTE. Be-
sides use of antiplatelet, the independent variables tested for 
the multivariate logistic regression analyses included age, gen-
der, and BMI, as confounding factors (Table 3). The value of R2 
coefficient for this multivariate regression model was 0.009, sug-
gesting that this multivariate model would explain the variation 
of the outcome variable to the extent of 0.9%.
  After multivariate logistic regression analyses, use of antiplate-
Table 1. Characteristics of antiplatelet users and non-users
Parameters  Antiplatelet users Non-users
Gender
   Male
   Female
 
  72
173
 
165
414
Age (yr) 77.6 (50-94) 75.2 (17-107)
BMI (kg/m
2)       22.1 (14.4-31.4)     21.3 (12.1-29.8)
BMI, body mass index.Ji H-M, et al.  •  Symptomatic Venous Thromboembolism after Hip Fracture Surgery
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let was not associated with symptomatic VTE in HFS patients 
(P = 0.841).
 
DISCUSSION
In this study, the overall incidence of symptomatic VTE follow-
ing HFS was 4.4% (38/858), and the perioperative use of anti-
platelet did not reduce the incidence of symptomatic VTE after 
HFS in Korean patients.
  Pulmonary Embolism Prevention (PEP) study, which com-
pared the efficacy of low-dose aspirin and placebo in patients 
undergoing HFS, presented that the aspirin reduced the risk of 
VTE (12). However, the symptomatic VTE after HFS was not re-
duced in Korean patients who received antiplatelet agent includ-
ing aspirin in this study.
  On the other hand, the 4.4% overall incidence of VTE in this 
study is lower than that (46%-60%) after HFS without thrombo-
prophylaxis in Western patients, and comparable with that (1.3%- 
6%) after HFS in Western patients, who underwent routine throm-
boprophylaxis (1, 12-16). Although several risk factors for VTE 
have been presented by previous studies, there was no signifi-
cant risk factor of VTE in HFS after multivariate analysis in this 
study.
  In terms of HFS, recent Asian studies suggested that the inci-
dence of VTE in Asian patients was similar to that reported from 
the West (17-21) (Table 4). However, the majority of these stud-
ies mainly focused on other procedure such as total knee arthro-
plasty and total hip arthroplasty, and had too small size of HFS. 
In addition, most studies used data collected from various areas 
of Asia and included multiple ethnic groups other than East 
Asian. In the AIDA study, which evaluated asymptomatic VTE 
in 837 Asian patients undergoing orthopedic surgery in 19 cen-
ters in 7 Asian countries, the rate of asymptomatic DVT in 96 
HFS without thromboprophylaxis was 42.0%, which was simi-
lar to that from West (Table 4) (20).
  Although the incidence (4.4%) of symptomatic VTE in this 
study was lower than those of the Western studies, our results 
do not indicate that thromboprophylaxis after HFS is not neces-
sary in Korean patients, because the incidence of symptomatic 
VTE will always be markedly lower than those of asymptomatic 
VTE, that are venographically proved. In contrast to elective to-
tal hip arthroplasty, the patients with HFS were extremely old 
and had several co-morbidities such as diabetes and cardiovas-
Table 2. Univariate comparisons between VTE group and non-VTE group
Variables 
VTE group 
(n = 38)
Non-VTE group 
(n = 820)
P value
Gender
   Male
   Female
  6
32
236
584
0.097
Age (yr) 79.1 ± 9.8   75.9 ± 12.2 0.115
BMI (kg/m
2) 22.2 ± 4.1 21.5 ± 3.7 0.235
Koval classification   2.4 ± 1.7   2.5 ± 1.9 0.894
Diagnosis
   Femoral neck fracture
   Intertrochanteric fracture
 
15
23
 
362
458
0.619
Pathologic fracture
   No
   Yes
 
38
  0
 
801
  18
1.000
Malignancy
   No
   Yes
 
33
  5
 
752
  68
0.364
Type of operation
   Arthroplasty
   Internal fixation
 
34
  4
 
655
165
0.208
Anesthesia
   Regional (spinal/epidural)
   General
 
36
  2
 
701
119
0.150
ASA   2.3 ± 0.6   2.2 ± 0.7 0.683
Operation time (min)   87.6 ± 23.2   95.7 ± 36.8 0.202
Duration from fracture to operation 
   (days)
    8.4 ± 12.8   10.3 ± 36.7 0.753
Previous cardiovascular or 
   cerebrovascular disease
   No
   Yes
 
32
  6
 
662
158
0.832
Antiplatelet
   User
   Non-user
 
12
26
 
238
582
0.718
VTE, venous thromboembolism; BMI, body mass index; ASA, American Society of An-
esthesiologists.
Table 3. Multivatriate analysis for symptomatic VTE
Variables  Odds ratio (95% CI) P value
Male 0.548 (0.223-1.346) 0.189
Age 1.031 (0.994-1.346) 0.101
BMI 1.066 (0.976-1.164) 0.157
Use of antiplatelet 0.930 (0.457-1.893) 0.841
VTE, venous thromboembolism; CI, confidence interval; BMI, body mass index.
Table 4. Incidence of symptomatic VTE after hip fracture surgery in previous studies and the current study
Authors (reference No.) No. of HFS No. of VTE (%) No. of DVT (%) No. of PE (%)
Atichartakarn et al. (1988) (17)   29 2 (6.9)* 0 (0) NA
Mitra et al. (1988) (18)   72 7 (9.7)* 7 (9.7)* 0
Dhillon et al. (1996) (19)   40 20 (50)* 20 (50)* 0
Piovella et al. (2005) (20)   96 40 (42)* 40 (42)* NA
Bagaria et al. (2006) (21) 102 7 (6.8)* 7 (6.8)* 0
Current study 858 38 (4.4) 30 (3.5) 21 (2.4)
*Including asymptomatic DVT. VTE, venous thromboembolism; HFS, hip fracture surgery; THA, total hip arthroplasty; DVT, deep vein thrombosis; PE, pulmonary embolism; NA, 
not available.Ji H-M, et al.  •  Symptomatic Venous Thromboembolism after Hip Fracture Surgery
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cular diseases. If these patients suffered symptomatic VTE, their 
recovery of ambulatory ability prior to injury would be delayed 
during rehabilitation, and the mortality of the patients with os-
teoporotic hip fracture would be increased (9, 22).
  This study has several limitations. First, our study was not a 
prospective but a retrospective study. However, a prospective 
randomized comparative study is barely possible in these senile 
patients who have a lack of perception on participation. Second, 
we could not perform VTE studies in asymptomatic patients and 
did not determine the incidence of asymptomatic VTE. How-
ever, VTE studies are associated with procedure-related com-
plications and high medical cost (23, 24), and objectives of pro-
phylaxis in VTE are to prevent fatal PE and to reduce the symp-
tomatic morbidity associated with VTE (25). Therefore, our study 
on symptomatic VTE in patients with HFS might be justified. 
Third, subgroup analyses according to antiplatelet agents and 
their doses were not performed because our patients were treat-
ed with various agents and the number of symptomatic patients 
was small. Fourth, we did not evaluate the patients’ compliance 
in terms of the antiembolic stockings and the ankle pump, which 
might be a confounding factor for VTE development.
  Although antiplatelet therapy has been shown to reduce the 
risk of arterial occlusive disease (6, 7, 26), it is controversial wheth-
er the antiplatelet agents are effective or not in the prevention 
of VTE (12, 27, 28). It might be argued that the antiplatelet users 
in our study might have a previous history of major arterial oc-
clusive diseases including cerebrovascular or cardiovascular dis-
ease and were more vulnerable to VTE. However, univariate 
analysis in our study showed that previous arterial disease was 
not associated with an increased risk of VTE.
  The incidence of hip fracture will increase in accordance with 
prolonged life expectancy in East Asia (29, 30), and VTE after 
HFS appears as an important medical issue. Our study showed 
that antiplatelets are not effective in the prevention of symptom-
atic VTE after HFS, although the incidence of symptomatic VTE 
after HFS was low. The data of current study could be used for 
the thromboprophylactic guideline of in Korean patients with 
HFS. 
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